NCT01070485已完成2 期
An Open-label Phase IIa, Non-randomized Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 23
- 主要终点
- Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)
研究概览
简要总结
The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Xofigo (Alpharadin) will be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patient is female, and either post-menopausal (cessation of menses for more than 1 year) or surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of childbearing potential the result of a urine human chorionic gonadotropin pregnancy test, performed on the same day as and with the result known before study drug administration, must be negative.
- •Histological or cytological evidence of primary breast cancer.
- •Bone dominant disease (with or without metastases in soft tissue, lymph nodes and/or skin) with at least one non-irradiated bone metastasis on planar bone scintigraphy/SPECT ± CT within previous the 12 weeks.
- •Patient has unequivocally progressed on endocrine therapy and further benefit from endocrine therapy is considered unlikely (progression must be documented based on imaging and/or other clinically relevant information).
- •Patient has been on bisphosphonate therapy for at least 3 months prior to treatment start and no change to bisphosphonate therapy is expected during the treatment phase of the study, or patient is not being treated with bisphosphonates, and such treatment is not planned to start during the treatment period.
- •Latest endocrine therapy stopped at least 2 weeks prior to treatment start.
- •ECOG PS 0 -
- •Life expectancy ≥6 months.
- •Patient fulfils the following certain laboratory requirements.
排除标准
- •Received an investigational drug within 4 weeks prior to the administration of Alpharadin, or is scheduled to receive one during the treatment period.
- •Received chemotherapy, immunotherapy, or external beam radiation therapy within the last 4 weeks prior to administration of study drug, or has not recovered from acute ARs as a result of such therapy.
- •Is likely to require chemotherapy or immunotherapy within the 16 weeks treatment period.
- •Presence of imminent or established spinal cord compression based on clinical findings and/or MRI.
- •Presence of other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not breast cancer metastases.
- •Presence of unequivocal visceral metastases requiring chemotherapy treatment in the next 6 months, based on Investigator's judgement. Brain metastases are allowed only if well controlled and if not associated with symptoms. Treatment for brain metastasis should have been completed at least 8 weeks prior to treatment start.
- •Patients with any other serious illness or medical condition, such as:
- •any uncontrolled infection
- •clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or heart failure more severe than this (NYHA Heart Failure Class III or IV)
- •Crohn's disease or ulcerative colitis
- •Bone marrow myelodysplasia
- •Unmanageable faecal incontinence
研究组 & 干预措施
Radium-223 dichloride (Xofigo, BAY 88-8223)
Experimental
Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
干预措施: Radium-223 chloride (BAY88-8223) (Drug)
结局指标
主要结局
Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)
时间窗: 16 weeks
次要结局
- Pain(1 year)
- All safety data, including adverse events, changes in laboratory variables, vitals signs, physical examination, late toxicity(1 year)
- Biochemical markers (additional bone markers and CA15.3)(16 weeks)
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(1 year)
研究者
相似试验
已完成
2 期
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT02554019Biotest36
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT02077465Gilead Sciences11
已完成
1 期
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or PolymyositisDERMATOMYOSITIS OR POLYMYOSITISNCT00533091MedImmune LLC51
已完成
2 期
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional TherapyGoutNCT00080210Savient Pharmaceuticals40
已完成
2 期
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)HypercholesteremiaNCT02722408NeuroBo Pharmaceuticals Inc.8